SGLT2 Inhibitors, Finerenone and Semaglutide Differ

Different drugs, different cardiorenal signals

The meta-analysis assembled data from 37,923 participants with cardiorenal disease across 10 randomized datasets. Its central message is not that one therapy dominates every outcome. Instead, the available evidence separates into recognizable patterns: SGLT2 inhibitors have the most established signal for slowing chronic kidney disease progression and reducing heart failure events; finerenone provides kidney and cardiovascular protection in type 2 diabetes with chronic kidney disease; and semaglutide adds atherosclerotic cardiovascular, mortality and kidney evidence in people with type 2 diabetes and chronic kidney disease.

That distinction matters clinically. A composite labeled “cardiovascular benefit” may be driven by fewer heart failure hospitalizations in one program and fewer atherosclerotic events in another. Kidney composites also vary in their estimated glomerular filtration rate thresholds, inclusion of kidney failure or cardiovascular death, and dependence on investigator-reported outcomes. Similar-looking hazard ratios therefore do not necessarily describe the same benefit.

The major trials anchoring the comparison illustrate the differences.

These trial estimates provide context rather than a valid head-to-head ranking. The populations, background care, outcome definitions and follow-up periods were not identical. DAPA-CKD and EMPA-KIDNEY also enrolled participants without diabetes, whereas the pivotal finerenone and semaglutide kidney programs focused on type 2 diabetes.

How the comparison should be read

The analysis is a meta-analysis of randomized datasets, not a randomized trial assigning participants directly among an SGLT2 inhibitor, finerenone and semaglutide. Randomization supports causal estimates within each original trial against its assigned comparator. It does not preserve randomization when investigators compare effect estimates across separate trial programs.

That boundary is important. Differences between therapies may reflect pharmacology, but they may also reflect who qualified for each trial, baseline cardiovascular risk, albuminuria, kidney function, background renin-angiotensin system therapy, event definitions and the period in which the study was conducted. Cross-trial comparisons can identify patterns and generate a more coherent evidence map, but they cannot prove that one drug would outperform another in the same patient.

The kidney evidence for SGLT2 inhibition is broad because dedicated trials included CKD with and without diabetes and consistently captured clinically important loss of kidney function. The class also has a well-established heart failure signal, which should not be collapsed into the same category as prevention of myocardial infarction or stroke.

Finerenone addresses a different evidence-defined population. The FIDELITY analysis pooled two complementary randomized trials of adults with type 2 diabetes across a spectrum of CKD. Finerenone reduced both a cardiovascular composite and a kidney composite, but its cardiovascular result included heart failure hospitalization alongside cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Hyperkalemia remains a treatment-specific consideration that cannot be inferred from efficacy estimates alone.

Semaglutide’s FLOW trial added dedicated kidney-outcomes evidence to an existing cardiovascular program. Its primary composite included kidney disease outcomes and cardiovascular death, while secondary analyses supported cardiovascular and survival benefits. This creates a clinically relevant profile for patients in whom type 2 diabetes, CKD, excess weight and atherosclerotic cardiovascular risk overlap. It does not make semaglutide a direct substitute for an SGLT2 inhibitor or finerenone.

Implications for treatment strategy

The evidence supports an outcome-first approach. When heart failure prevention or broad CKD progression is the central concern, the SGLT2 inhibitor trial portfolio is particularly applicable. For persistent albuminuric CKD associated with type 2 diabetes, finerenone provides evidence from a specifically defined population. Semaglutide may be especially relevant when kidney risk coexists with a need to reduce major cardiovascular risk and improve metabolic control.

These are not necessarily either-or choices. The drugs act through different pathways, and contemporary care may involve layered therapy when indications overlap and tolerability permits. However, the comparative meta-analysis should not be read as proving the benefit of every combination. Most pivotal trials were not designed or powered to isolate interaction effects among all three strategies, and background use of newer cardiorenal therapies varied.

Policy decisions should preserve these distinctions as well. A single broad category of “cardiorenal protective drugs” can obscure differences in eligible populations, monitoring needs and the outcomes most directly supported by randomized evidence. Formulary comparisons based only on a composite hazard ratio risk treating clinically different endpoints as equivalent.

Limits that remain important

The principal limitation is the lack of direct, adequately powered randomized comparisons among the three strategies. Meta-analytic estimates may be affected by heterogeneity in participant characteristics, endpoint construction, background therapy and follow-up. Drug-class conclusions may also be less secure when evidence is concentrated in particular agents or trial populations.

Generalizability requires care. Finerenone and FLOW evidence applies most directly to type 2 diabetes with CKD, while SGLT2 inhibitor kidney trials extend beyond diabetes. Participants in randomized trials receive structured monitoring and may not represent people with advanced frailty, extensive multimorbidity or limited access to laboratory follow-up. Funding and investigator conflicts should be assessed in the meta-analysis and each contributing trial because the pivotal development programs were industry sponsored.

The analysis also cannot determine the best treatment sequence. Trials designed around combination use, treatment order and patient-centered trade-offs would be needed to answer whether starting one strategy before another changes long-term cardiovascular or kidney outcomes.

Questions clinicians ask

Does the meta-analysis show that one therapy is best overall?

No. It compares patterns across randomized datasets with different populations and endpoints, rather than randomizing the same population among the three therapies. The evidence is more useful for identifying which outcomes and patient groups are best represented than for declaring a universal winner.

Are the cardiovascular outcomes interchangeable?

No. SGLT2 inhibitor programs are especially notable for heart failure outcomes, while semaglutide has evidence encompassing major atherosclerotic events and mortality. Finerenone reduced a cardiovascular composite that included heart failure hospitalization. The component outcomes should be reviewed before translating a composite result into a treatment priority.

Can these therapies be used as layered treatment?

Potentially, when their evidence-based populations overlap, but the meta-analysis does not establish the efficacy of every combination or sequence. Different mechanisms make layering clinically plausible, while kidney function, potassium, volume status, metabolic goals, adverse effects, access and the monitoring required for each therapy remain relevant.

Which evidence applies beyond type 2 diabetes?

The strongest randomized evidence beyond diabetes comes from SGLT2 inhibitor CKD programs, including DAPA-CKD and EMPA-KIDNEY. The pivotal finerenone CKD program and FLOW semaglutide trial enrolled people with type 2 diabetes, so extrapolating their kidney results to CKD without diabetes would go beyond those trial populations.

References

1. Comparative cardiorenal meta-analysis of SGLT2 inhibitors, finerenone, and semaglutide — National Library of Medicine (PubMed), 2026 2. Dapagliflozin in Patients with Chronic Kidney Disease — The New England Journal of Medicine, 2020 3. Empagliflozin in Patients with Chronic Kidney Disease — The New England Journal of Medicine, 2023 4. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis — European Heart Journal, 2022 5. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes — The New England Journal of Medicine, 2024